Home/Pipeline/Avarept® Ophthalmic suspension 0.3%

Avarept® Ophthalmic suspension 0.3%

Dry Eye Disease

ApprovedActive

Key Facts

Indication

Dry Eye Disease

Phase

Approved

Status

Active

Company

Senju Pharmaceutical

About Senju Pharmaceutical

Senju Pharmaceutical is a long-established, specialized ophthalmology company with a global footprint, headquartered in Japan and operating in Fort Worth, USA. It has a diversified portfolio spanning prescription drugs, OTC products, and a robust R&D pipeline targeting conditions like dry eye disease and glaucoma. The company demonstrates commercial execution through recent product approvals and strategic licensing agreements, positioning it in the growing global eye care market.

View full company profile

Therapeutic Areas

Ophthalmology

Other Dry Eye Disease Drugs

Drug	Company	Phase	Status
Elate Ocular®	Cambium Bio	Phase 3	Active
OT-301	Ocumension Therapeutics	Phase 2	Active
Dry Eye Care Portfolio	YD Bio	Commercial	Active
Dry Eye Studies	Oculus Research	Not Applicable (Service Provider)	Active
MediPrint Lens (Dry Eye)	MediPrint Ophthalmics	Pre-clinical/Research	Active
Tivanisiran	Sylentis	Phase 2/3	Active
A197	Aramis Biosciences	Phase 2	Active
KM102	Theratome Bio	Pre-clinical	Active
iTEAR®100 Commercialization	Olympic Ophthalmics	Commercial	Active
HydraD	EyeD Pharma	Pre-Clinical	Active
ST-100 (Vezocolmitide)	Stuart Therapeutics	Phase 3	Active
BRM421	BRIM Biotechnology	Phase 3	Active (Second Phase 3 trial application submitted 2025)